Published online Feb 27, 2024. doi: 10.4240/wjgs.v16.i2.518
Peer-review started: December 12, 2023
First decision: January 2, 2024
Revised: January 13, 2024
Accepted: January 24, 2024
Article in press: January 24, 2024
Published online: February 27, 2024
Processing time: 75 Days and 6.7 Hours
Gastric cancer is a leading cause of cancer-related deaths worldwide. Prognostic assessments are typically based on the tumor-node-metastasis (TNM) staging system, which does not account for the molecular heterogeneity of this disease. LATS2, a tumor suppressor gene involved in the Hippo signaling pathway, has been identified as a potential prognostic biomarker in gastric cancer.
To construct and validate a nomogram model that includes LATS2 expression to predict the survival prognosis of advanced gastric cancer patients following ra
A retrospective analysis of 245 advanced gastric cancer patients from the Fourth Hospital of Hebei Medical University was conducted. The patients were divided into a training group (171 patients) and a validation group (74 patients) to deve
The model demonstrated a high predictive accuracy with C-indices of 0.829 in the training set and 0.862 in the validation set. Area under the curve values for three-year and five-year survival prediction were significantly robust, suggesting an excellent discrimination ability. Calibration plots confirmed the high concordance between the predictions and actual survival outcomes.
We developed a nomogram model incorporating LATS2 expression, which significantly outperformed conventional TNM staging in predicting the prognosis of advanced gastric cancer patients postsurgery. This model may serve as a valuable tool for individualized patient management, allowing for more accurate stratification and im
Core Tip: This study focuses on developing a prognostic model for patients with advanced gastric cancer postsurgery by integrating LATS2 expression and clinicopathological features into a nomogram. It highlights the significance of the LATS2 gene in improving prognostic predictions beyond traditional tumor-node-metastasis staging. Our model demonstrates excellent predictive accuracy and clinical utility, which indicates its potential for enhancing individualized patient care through better risk stratification. Future studies should focus on external validation to confirm the model’s applicability across diverse patient populations.
